• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human Resources Compliance Library >Gilead double patenting rule only applies to patents filed after URAA’s effective date
【24h】

Gilead double patenting rule only applies to patents filed after URAA’s effective date

机译：基双专利规则只适用于专利申请后URAA的生效日期

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The federal district court in Wilmington, Delaware, erred by finding that a patent owned by Novartis AG, filed after the June 8, 1995 effective date of the Uruguay Round Agreements Act (URAA), was an invalidating obviousnesstype double patenting reference for a related patent which expired earlier, the U.S. Court of Appeals for the Federal Circuit has ruled. The court clarified that its prior opinion in Gilead Sciences, Inc. v. Natco Pharma Ltd.—holding that the expiration date is the benchmark of obviousness-type double patenting—is limited to the context when both patents in question are post-URAA patents. This case involved one pre-URAA patent and one post-URAA patent governed by different patent term statutory regimes. Under the circumstances, the correct framework was to apply the traditional pre-URAA framework and look to issuance date as the reference point for obviousness-type double patenting (Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical, Inc., December 7, 2018, Chen, R.).
机译：威尔明顿的联邦地区法院特拉华,犯了错误被发现拥有的专利诺华公司,申请在6月8日,1995年乌拉圭回合协议的生效日期法》(URAA),是一个使obviousnesstype失效双专利参考相关的专利过期前,美国上诉法院吗联邦巡回法院裁定。澄清之前,其观点在基列地科学公司诉Natco制药Ltd.-holding到期日期的基准obviousness-type专利权限制的两倍当专利问题都是上下文post-URAA专利。pre-URAA专利和一个post-URAA专利管理由不同的专利项法定制度。这种情况下,正确的框架应用传统pre-URAA框架和看发行日期的参考点obviousness-type双专利(诺华制药公司诉出台制药公司,2018年12月7日,陈,r .)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号